Avior Wealth Management LLC Has $574,000 Stock Position in Insulet Co. (NASDAQ:PODD)

Avior Wealth Management LLC lifted its stake in shares of Insulet Co. (NASDAQ:PODD) by 3.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,645 shares of the medical instruments supplier’s stock after purchasing an additional 91 shares during the quarter. Avior Wealth Management LLC’s holdings in Insulet were worth $574,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. Qube Research & Technologies Ltd increased its stake in shares of Insulet by 227.3% in the third quarter. Qube Research & Technologies Ltd now owns 386,687 shares of the medical instruments supplier’s stock valued at $61,673,000 after buying an additional 268,553 shares during the period. Assenagon Asset Management S.A. increased its stake in shares of Insulet by 119.1% in the 4th quarter. Assenagon Asset Management S.A. now owns 79,375 shares of the medical instruments supplier’s stock valued at $17,223,000 after acquiring an additional 43,147 shares in the last quarter. Asset Management One Co. Ltd. grew its stake in shares of Insulet by 33.7% in the 4th quarter. Asset Management One Co. Ltd. now owns 36,677 shares of the medical instruments supplier’s stock valued at $8,048,000 after buying an additional 9,240 shares during the period. Graham Capital Management L.P. grew its stake in Insulet by 689.8% in the third quarter. Graham Capital Management L.P. now owns 23,095 shares of the medical instruments supplier’s stock valued at $3,683,000 after acquiring an additional 20,171 shares during the period. Finally, Aquila Investment Management LLC bought a new position in shares of Insulet in the fourth quarter valued at $1,302,000.

Analysts Set New Price Targets

PODD has been the subject of several recent research reports. Robert W. Baird upgraded Insulet from a “neutral” rating to an “outperform” rating and upped their price target for the stock from $180.00 to $238.00 in a report on Thursday, December 21st. Piper Sandler dropped their price objective on Insulet from $250.00 to $230.00 and set an “overweight” rating for the company in a research note on Friday, February 23rd. JPMorgan Chase & Co. upped their target price on Insulet from $190.00 to $225.00 and gave the stock an “overweight” rating in a research note on Friday, February 23rd. Stifel Nicolaus lifted their price target on Insulet from $163.00 to $208.00 and gave the company a “hold” rating in a research report on Monday, February 5th. Finally, Barclays decreased their price objective on shares of Insulet from $214.00 to $213.00 and set an “equal weight” rating on the stock in a research report on Monday, February 26th. Four equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, Insulet presently has a consensus rating of “Moderate Buy” and a consensus price target of $243.21.

Insulet Trading Down 0.9 %

PODD stock opened at $164.73 on Friday. Insulet Co. has a one year low of $125.82 and a one year high of $335.91. The company has a market capitalization of $11.53 billion, a PE ratio of 56.61, a price-to-earnings-growth ratio of 2.99 and a beta of 0.98. The company’s 50 day moving average price is $174.50 and its two-hundred day moving average price is $178.80. The company has a debt-to-equity ratio of 1.86, a quick ratio of 2.62 and a current ratio of 3.51.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.73. Insulet had a net margin of 12.16% and a return on equity of 32.19%. The company had revenue of $509.80 million for the quarter, compared to analysts’ expectations of $461.26 million. During the same quarter last year, the company earned $0.55 EPS. The firm’s revenue was up 37.9% compared to the same quarter last year. As a group, analysts predict that Insulet Co. will post 3.08 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Shacey Petrovic sold 11,609 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $162.92, for a total value of $1,891,338.28. Following the transaction, the director now owns 2,567 shares in the company, valued at $418,215.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.90% of the company’s stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.